Overview

* LifeMD ( LFMD ) Q2 revenue rises 23% yr/yr but misses analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 up 223%, yet misses consensus estimates, per LSEG data

* Company fully repaid senior debt and launched new behavioral health services

Outlook

* LifeMD ( LFMD ) sees Q3 revenue between $61 mln and $63 mln

* Company expects Q3 telehealth revenue between $48 mln and $50 mln

* LifeMD ( LFMD ) anticipates full-year revenue between $250 mln and $255 mln

* Company forecasts full-year telehealth revenue between $195 mln and $200 mln

Result Drivers

* TELEHEALTH GROWTH - Telehealth revenue increased 30% yr/yr, driven by new service offerings

* PLATFORM DIVERSIFICATION - Nationwide launch of behavioral health services and acquisition of women's health practice

* MEMBERSHIP ENHANCEMENT - Scaling of LifeMD+ membership program with expanded services

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $62.20 $66.30

Revenue mln mln (7

Analysts

)

Q2 Net -$2.90

Income mln

Q2 Miss $7.10 $7.84

Adjusted mln mln (6

EBITDA Analysts

)

Q2 Gross 88.0%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for LifeMD Inc ( LFMD ) is $14.00, about 11.8% above its August 4 closing price of $12.35

* The stock recently traded at 72 times the next 12-month earnings vs. a P/E of 314 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)